drugset / Trial / NCT00453973
Extension Study to Evaluate Safety and Tolerability of Peginesatide for Long-Term Treatment of Anemia in Participants With CKD (EU)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study was to evaluate the long term safety and tolerability of peginesatide for the maintenance of hemoglobin in participants with chronic kidney disease (CKD) who had received at least 24 weeks of peginesatide treatment in an earlier study.
Timeline
- Start
- 2006-11
- Primary completion
- 2009-09
- Completion
- 2009-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | peginesatide | Peptide | 0.024 mg/kg | Intravenous |
| Subject | peginesatide | Peptide | 0.044 mg/kg | Intravenous |